Cargene is a preclinical-stage biopharmaceutical company developing oligonucleotide therapeutics across a broad range of diseases and targeting a variety of organs and tissues.
With sites in Singapore, China and USA, Cargene leverages our chemistry and biological insights to deliver clinically meaningful treatments.
Cargene was founded by experienced biotech entrepreneurs XQ Lin, Dr. Yann Chong Tan, Professor Torsten Wuestefeld, and is advised by a world-class SAB including Professors Harvey Lodish, Roger Foo and Kosh Ray.
With sites in Singapore, China and USA, Cargene leverages our chemistry and biological insights to deliver clinically meaningful treatments.
Cargene was founded by experienced biotech entrepreneurs XQ Lin, Dr. Yann Chong Tan, Professor Torsten Wuestefeld, and is advised by a world-class SAB including Professors Harvey Lodish, Roger Foo and Kosh Ray.
Location: Singapore
Employees: 11-50
Total raised: $19.2M
Investors 1
| Date | Name | Website |
| - | EVX Ventur... | evx.ventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.12.2021 | Series A | $19.2M | BioTrack C... |
Mentions in press and media 4
| Date | Title | Description |
| 24.04.2023 | The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033 | - |
| 15.12.2021 | Cargene Biopharma Raises US$19.2M in Pre-A Funding Round | Cargene Biopharma, a Singapore-based preclinical-stage biopharmaceutical company, raised US$19.2M in Pre-A funding. The round was led by BioTrack Capital, with participation from Hyfinity Investments, Legendstar Capital. The company intends... |
| 14.12.2021 | Cargene Closes a US$19.2M Pre-A Round Led by BioTrack Capital | SINGAPORE and SHANGHAI and BOSTON, Dec. 14, 2021 /PRNewswire/ -- Cargene Biopharma Inc. ("Cargene") announced today the close of an over-subscribed US$19.2 million pre-Series A funding round. The financing was led by BioTrack Capi... |
| 14.12.2021 | Cargene Closes a US$19.2M Pre-A Round Led by BioTrack Capital | SINGAPORE and SHANGHAI and BOSTON, Dec. 14, 2021 /PRNewswire/ -- Cargene Biopharma Inc. ("Cargene") announced today the close of an over-subscribed US$19.2 million pre-Series A funding round. The financing was led by BioTrack Capi... |